Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I3/191

[1] 杜慧,鲍永波.头孢哌酮钠舒巴坦钠致新生儿凝血功能异常36例分析[J].药物不良反应杂志,2013, 15(3):148-151.
[2] 许亚梅,寇兰俊,杭海燕.头孢哌酮钠/舒巴坦钠静脉输注致严重凝血功能障碍[J].药物不良反应杂志,2011,13(5):315-316.
[3] 蒋红,陈井霞,权秦,等.头孢哌酮钠/舒巴坦钠对凝血功能的影响及处理[J].药学服务与研究, 2016, 16(4):300-303.
[4] Alitalo R, Ruutu M, Valtonen V, et al. Hypoprothrombi-naemia and Bleeding during Administration of Cefaman-dole and Cefoperazone. Report of Three Cases [J]. Ann Clin Res, 1985, 17(3): 116-119.
[5] 戴晓琴,马纯雪,蔡月,等.头孢哌酮钠舒巴坦钠致凝血功能异常的危险因素分析及护理[J].护理学报, 2013,20(5A):59-61.
[6] 刘云芳,杨舒. β-内酰胺类抗生素对凝血功能影响的研究[J].现代检验医学杂志, 2008, 23(4):118-119.
[7] 卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆出版社, 2009: 65.
[8] 张广求,张筱萌.头孢哌酮舒巴坦导致消化道出血1例[J].中国处方药, 2012, 10(1):14-15.
[9] 常剑锋,黄宇烽,郑钧.大剂量β-内酰胺类抗生素对凝血试验的干扰[J].临床检验杂志, 2000, 18(4):210-212.
[10] 王艳宁,钟慧.头孢哌酮/舒巴坦钠致凝血功能异常4例[J].中国药房, 2005, 16(17):1329-1330.
[11] 王艳宁,钟慧.头孢哌酮/舒巴坦钠致凝血功能障碍临床分析[J].中国药物应用与监测, 2005, 2(5):54-55.
[12] 刘宪军,付娜. 109例头孢哌酮钠舒巴坦钠不良反应报告分析[J].中国药物警戒, 2014, 11(6):355-357.
[13] 乔莉,刘先华.头孢哌酮钠-舒巴坦钠致凝血功能异常一例分析并文献复习[J].临床误诊误治, 2016, 29(3):90-92.
[14] 朱爱华,时晶,倪敬年,等.头孢哌酮钠/舒巴坦钠致凝血功能异常[J].药物不良反应杂志,2011, 13(6):373-374.
[15] 谭清武,李庆华.头孢哌酮钠舒巴坦钠致严重凝血功能障碍[J].药物不良反应杂志, 2005, 7(3):210-211.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.